Theravance Biopharma公司宣布，其股东将有权获得一项或有价值权（CVR），该权利与Ampreloxetine资产变现所产生的净收益挂钩。具体而言，股东将有权分享该资产净收益的80%。这一安排旨在将未来潜在的价值创造直接回馈给公司股东。
Theravance Biopharma公司宣布，其股东将有权获得一项或有价值权（CVR），该权利与Ampreloxetine资产变现所产生的净收益挂钩。具体而言，股东将有权分享该资产净收益的80%。这一安排旨在将未来潜在的价值创造直接回馈给公司股东。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.